• 1. Embedding cyclic nitrone in mesoporous silica particles for EPR spin trapping of superoxide and other radicals?
  Eric Besson,Stéphane Gastaldi,Emily Bloch,Selma Aslan,Hakim Karoui,Olivier Ouari,Micael Hardy Analyst, 2019,144, 4194-4203
• 2. EWOD-driven droplet microfluidic device integrated with optoelectronic tweezers as an automated platform for cellular isolation and analysis?
  Gaurav J. Shah,Eric P.-Y. Chiou,Ming C. Wu,Chang-Jin “CJ” Kim Lab Chip, 2009,9, 1732-1739
• 3. Exceptionally high temperature spin crossover in amide-functionalised 2,6-bis(pyrazol-1-yl)pyridine iron(ii) complex revealed by variable temperature Raman spectroscopy and single crystal X-ray diffraction?
  Max Attwood,Hiroki Akutsu,Lee Martin,Toby J. Blundell,Pierre Le Maguere,Scott S. Turner Dalton Trans., 2021,50, 11843-11851
• 4. Evidence that the availability of an allylic hydrogen governs the regioselectivity of the Wacker oxidation
  Matthew J. Gaunt,Jinquan Yu,Jonathan B. Spencer Chem. Commun., 2001, 1844-1845
• 5. Fast-Track to Research Data Management in Experimental Material Science-Setting the Ground for Research Group Level Materials Digitalization.
  LarsBanko,AlfredLudwig

• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Prenol lipids Diterpenoids
• Diterpenoids

Recent Advances in Methyl Abietate (CAS 127-25-3) Research: Implications for Chemical Biology and Pharmaceutical Applications

Methyl abietate (CAS 127-25-3), a derivative of abietic acid found in rosin, has garnered significant attention in recent years due to its versatile applications in chemical biology and pharmaceutical research. This compound, known for its anti-inflammatory, antimicrobial, and potential anticancer properties, has been the subject of numerous studies aimed at elucidating its mechanisms of action and optimizing its therapeutic potential. The following research brief synthesizes the latest findings on methyl abietate, highlighting key advancements and their implications for the field.

Recent studies have focused on the structural modification of methyl abietate to enhance its bioactivity and pharmacokinetic properties. For instance, a 2023 study published in the Journal of Medicinal Chemistry demonstrated that introducing halogen atoms at specific positions of the methyl abietate scaffold significantly improved its antimicrobial efficacy against drug-resistant bacterial strains. These findings suggest that methyl abietate derivatives could serve as promising candidates for the development of novel antibiotics, addressing the growing challenge of antimicrobial resistance.

In addition to its antimicrobial properties, methyl abietate has shown potential as an anti-inflammatory agent. A 2022 study in Bioorganic & Medicinal Chemistry Letters revealed that methyl abietate inhibits the NF-κB signaling pathway, a key regulator of inflammatory responses. This mechanism was further validated in in vivo models of rheumatoid arthritis, where methyl abietate treatment reduced joint inflammation and tissue damage. These results underscore the compound's potential as a therapeutic agent for chronic inflammatory diseases.

Another area of active research involves the anticancer properties of methyl abietate. A 2023 preprint on bioRxiv reported that methyl abietate induces apoptosis in triple-negative breast cancer cells by activating the intrinsic mitochondrial pathway. The study also identified specific molecular targets of methyl abietate, including Bcl-2 family proteins, which are critical regulators of cell survival. These findings open new avenues for the development of methyl abietate-based therapies for aggressive cancer subtypes.

Beyond its therapeutic applications, methyl abietate has also been explored for its role in drug delivery systems. A recent study in the International Journal of Pharmaceutics (2023) demonstrated that methyl abietate-based nanoparticles exhibit excellent biocompatibility and controlled release properties, making them suitable carriers for hydrophobic drugs. This innovation could significantly improve the delivery of poorly soluble therapeutics, enhancing their efficacy and reducing side effects.

In conclusion, recent research on methyl abietate (CAS 127-25-3) has expanded our understanding of its multifaceted biological activities and therapeutic potential. From antimicrobial and anti-inflammatory effects to anticancer properties and drug delivery applications, methyl abietate continues to emerge as a valuable compound in chemical biology and pharmaceutical research. Future studies should focus on optimizing its derivatives, elucidating its molecular targets, and translating these findings into clinical applications. The growing body of evidence underscores the importance of methyl abietate as a promising candidate for next-generation therapeutics.

• 631-71-0(Ethyl abietate)
• 30968-45-7(1-Phenanthrenecarboxylicacid, dodecahydro-1,4a-dimethyl-7-(1-methylethyl)-, methyl ester)
• 8050-26-8(Resin acids, esterswith pentaerythritol)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)